SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody, Mouse MAb (40143-MM05)
SARS-CoV/SARS-CoV-2 Nucleocapsid抗体, Mouse MAb
用户验证的应用
经验证应用
| 项目 | 详情 |
|---|---|
| WB | 1:1000-1:10000 |
| ELISA | 1:1000-1:2000 |
| IHC-P | 1:1000-1:5000 |
| FCM | 1:25-1:100 |
应用说明
(Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.)
推荐稀释说明
Optimal concentrations/dilutions should be determined by the end user.
详细信息
特异性
SARS-CoV Nucleocapsid Has cross-reactivity in ELISA and WB with SARS-CoV-2 Nucleocapsid Protein (Cat# 40588-V08B) Has cross-reactivity in ELISA with SARS-CoV-2 Omicron (B.1.1.529) Nucleocapsid Protein (Cat# 40588-V07E34) SARS-CoV-2 Omicron (BA.2) Nucleocapsid Protein (Cat# 40588-V07E35) SARS-CoV-2 Omicron XE(BA.1 x BA.2) Nucleocapsid Protein (Cat# 40588-V07E36) SARS-CoV-2 Omicron (BA.4) Nucleocapsid Protein (Cat# 40588-V07E37) SARS-CoV-2 Delta (B.1.617) Nucleocapsid (D377Y) Protein (Cat# 40588-V07E16) SARS-CoV-2 Delta (B.1.617) Nucleocapsid (R203M, D377Y) Protein (Cat# 40588-V07E20) SARS-CoV-2 Delta (B.1.617.2) Nucleocapsid Protein (Cat# 40588-V07E29) SARS-CoV-2 Delta (B.1.617.3) Nucleocapsid (P67S, R203M, D377Y) Protein (Cat# 40588-V07E30) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(R203K, G204R) Protein (Cat# 40588-V07E1) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(I292T) Protein (Cat# 40588-V07E4) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(D3L, R203K, G204R, S235F) Protein (Cat# 40588-V07E7) SARS-CoV-2 Alpha (B.1.1.7) Nucleocapsid(D3L, S235F) Protein (Cat# 40588-V07E8) SARS-CoV-2 Alpha(B.1.1.7/ B.1.237) Nucleocapsid(S194L) Protein (Cat# 40588-V07E3) SARS-CoV-2 Alpha/beta(B.1.1.7/ B.1.351/ A.2.2) Nucleocapsid(P13L) Protein (Cat# 40588-V07E2) SARS-CoV-2 Beta(B.1.351/B.1.351.2/b.1.351.3/B.1.427/B.1.429) Nucleocapsid (T205I) Protein (Cat# 40588-V07E9) SARS-CoV-2 Gamma(P.1/ P.1.1/ P.1.2) Nucleocapsid (P80R) Protein (Cat# 40588-V07E11) SARS-CoV-2 Eta(B.1.525) Nucleocapsid (A12G, T205I) Protein (Cat# 40588-V07E19) SARS-CoV-2 Nucleocapsid Protein (Cat# 40588-V07E) No cross-reactivity in ELISA with MERS-CoV Nucleocapsid protein (40068-V08B) HCoV-229E Nucleocapsid protein (40640-V07E) HCoV-NL63 Nucleocapsid protein (40641-V07E) HCoV-HKU1(isolate N5) Nucleocapsid protein (40642-V07E) HCoV-OC43 Nucleocapsid protein (40643-V07E)
制备方法
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant SARS-CoV Nucleoprotein / NP (Catalog#40143-V08B; NP_828858.1; Met1-Ala422). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
运输条件
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
背景信息
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool. References 1.Van Boheemen S, et al. (2012), MBio. 3(6):e00473-12. Bisht H. et al., 2004, Proc Natl Acad Sci. 101 (17): 6641-6. Li W. et al., 2005, Science. 309 (5742): 1864-8.
文献引用 (128)
Neuroendocrine cells orchestrate regeneration through Desert hedgehog signaling
神经内分泌细胞通过沙漠刺猬信号通路调控再生过程
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base
超强效SARS冠状病毒中和单域抗体,可阻断其刺突蛋白的基部。
Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies.
体细胞高频突变影响 SARS-CoV-2 中和抗体的病毒逃逸特性
Leveraged Vaccination to Alleviate Original Antigenic Sin for Enhancing Broad-Neutralizing Antibody Response against SARS-CoV-2 Omicron Subvariants.
利用疫苗接种减轻原始抗原罪,以增强针对 SARS-CoV-2 Omicron 亚型的广谱中和抗体反应
Interleukin-1 prevents SARS-CoV-2-induced membrane fusion to restrict viral transmission via induction of actin bundles
白细胞介素-1 通过诱导肌动蛋白束阻止 SARS-CoV-2 诱导的膜融合,从而限制病毒传播
A critical residue in a conserved RBD epitope determines neutralization breadth of pan-sarbecovirus antibodies with recurring YYDRxxG motifs.
保守的 RBD 表位中的一个关键残基决定了具有重复 YYDRxxG 基序的泛沙贝病毒抗体的中和广度
Syntaxin-6 restricts SARS-CoV-2 infection by facilitating virus trafficking to autophagosomes.
Syntaxin-6 通过促进病毒向自噬体运输来限制 SARS-CoV-2 感染
Role of N-linked glycosylation sites in human ACE2 in SARS-CoV-2 and hCoV-NL63 infection.
SARS-CoV-2 和 hCoV-NL63 感染中人类 ACE2 中 N-连接糖基化位点的作用
Host factor PLAC8 is required for pancreas infection by SARS-CoV-2
宿主因子 PLAC8 是 SARS-CoV-2 感染胰腺所必需的
Natural evidence of coronaviral 2'-O-methyltransferase activity affecting viral pathogenesis via improved substrate RNA binding.
冠状病毒 2'-O-甲基转移酶活性通过改善底物 RNA 结合影响病毒致病性的自然证据
- 1
- 2
- 3
- 4
- 5
- 6
- 13